KHKun Huang

Kun Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kun Huang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Pingwu Zhao

    Department of General Surgery, Affiliated Mianyang Hospital of Chengdu University of Traditional Chinese Medicine, Mianyang, China

    3 shared publications
  • Pan Zhao

    Department of General Surgery Mianyang Hospital of Traditional Chinese Medicine Mianyang Sichuan China

    2 shared publications
  • Xinzhu Yuan

    Department of Nephrology, The Second Clinical Medical Institution of North Sichuan Medical College (Nanchong Central Hospital) and Nanchong Key Laboratory of Basic Science & Clinical Research on Chronic Kidney Disease, Nanchong, Sichuan, P.R. China

    2 shared publications
  • Yunshen He

    Department of General Surgery Mianyang Hospital of Traditional Chinese Medicine Mianyang Sichuan China

    2 shared publications
  • Chao Hu

    Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province

    1 shared publication
  • Cheng-You Du

    The First Affiliated Hospital of Chongqing Medical University

    1 shared publication

Latest Publications

  • New‐Onset Diabetes and Pancreatic Ductal Adenocarcinoma: Implications for Early Recognition and Clinical Management

    by Kun Huang, Zhenghong Huang, Yunshen He, Pan Zhao, Xiaofeng Hu

    Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal because most patients are diagnosed after curative treatment is no longer feasible. Diabetes mellitus and PDAC have a bidirectional relationship: long‐standing type 2 diabetes mellitus (T2DM) modestly increases background cancer risk, whereas new‐onset diabetes (NOD), particularly after 50 years of age, may represent a paraneoplastic manifestation of occult PDAC. Population‐based data suggest that approximately 0.6%–0.85% of older adults with NOD are diagnosed with PDAC within 3 years. This absolute risk is too low to justify universal imaging, but high enough to support phenotype‐based triage. This review clarifies the distinction among T2DM, PDAC‐associated diabetes, type 3c diabetes mellitus related to non‐malignant exocrine pancreatic disease, and post‐pancreatectomy dysglycemia. We also summarise epidemiological and biological evidence connecting dysglycemia with PDAC, including insulin resistance, hyperinsulinemia, impaired insulin secretion, cachexia‐related metabolic change, and exocrine‐endocrine crosstalk. Particular emphasis is placed on selective diagnostic escalation. Age at diabetes onset, unintended weight loss, HbA1c or glucose trajectory, insulin resistance indices, biomarkers, and risk‐enrichment models, including the Enriching New‐Onset Diabetes for Pancreatic Cancer (END‐PAC) model, should be interpreted together rather than in isolation. Pancreas‐protocol computed tomography remains the first‐line diagnostic study when PDAC is suspected, while magnetic resonance imaging and endoscopic ultrasonography play complementary roles. We further discuss implications for pancreatic surgery, perioperative metabolic care, postoperative dysglycemia, and lessons from high‐risk surveillance cohorts. A diabetes‐centred framework may improve early recognition without promoting indiscriminate screening.


  • Open Access

    ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

    by Xiaohong Yi, Xianwen Zhang, Lijun Huang, Yuhui Chen, Maochun You, Hongyi Jia, Lefeng Hou, Chao Hu, Kun Huang, Yumei Wang

    Background: ZNF25 , a KRAB domain-containing zinc finger transcription factor, has been identified as a potential biomarker in ovarian cancer. However, its pan-cancer significance and the underlying molecular mechanisms in other malignancies remain largely unclear. Methods: We performed a systematic pan-cancer analysis of ZNF25 using TCGA and GTEx databases, integrated with platforms including cBioPortal, TISIDB, TIMER, and Sangerbox. Associations between ZNF25 expression and clinical outcomes, genomic alterations, immune cell infiltration, and DNA methylation were systematically evaluated. Based on these findings, functional validation was performed in glioma cell lines (U87-MG and A172) via siRNA-mediated knockdown of ZNF25 , followed by cell viability assays, wound healing assays, and Western blot assays. Additionally, RNA-seq was conducted in ZNF25 - knockdown U87-MG cells to identify differential expression genes and enriched pathways. Results: ZNF25 exhibited significant associations with diagnostic potential, poor prognosis, and immune infiltration across multiple cancer types, with the most pronounced effects observed in glioma. Functional assays demonstrated that ZNF25 knockdown suppressed the proliferation and migration of glioma cells. Transcriptomic and biochemical analysis indicated that ZNF25 promotes glioma progression, at least in part, through the positive modulation of the PI3K-AKT pathway. Conclusions: Collectively, our findings identify ZNF25 as a potential diagnostic and prognostic biomarker across various cancers and suggest its critical role in glioma progression. This study provides new insights into the functional role of ZNF25 and highlights its potential as a therapeutic target, particularly in glioma.

  • Open Access

    Development and validation of survival nomograms for patients with anaplastic thyroid carcinoma: a SEER program-based study

    by Xinming Chen, Pingwu Zhao, Yunsheng He, Kun Huang, Pan Zhao, Fengwan Liao, Yang Liu

    Background We aimed to study the prognostic risk factors affecting patients with anaplastic thyroid carcinoma (ATC), develop a clinical prognostic model, and assess patient survival outcomes. Methods Patients with anaplastic thyroid carcinoma from 2000 to 2019 were selected from the Surveillance, Epidemiology, and End Results (SEER) Program to extract the clinical variables used for analysis. The dataset was divided into training (70%) and validation (30%) sets based on a 7:3 ratio. Univariate and LASSO regression analyses were performed on clinical variables from the training set to identify independent prognostic factors. Independent prognostic factors were determined by Univariate and lasso regression according to the clinical variables of the training set, and a nomogram model was established to construct a prognostic model based on the contribution degree of the predictors. The prognostic model was evaluated and internally verified by C-index, ROC curve and calibration curve. Results A total of 713 ATC patients were included in the SEER database. LASSO regression results indicated that age, marital status, race, tumor size, whether the primary lesion was limited to the thyroid gland, surgery, radiotherapy and chemotherapy, were associated with overall survival(OS) prognosis of ATC, and were used to construct nomograms. In the training cohort, the OS nomogram’s C-index was 0.708 (95% CI 0.672–0.745); in the internal validation cohort, the C-index was 0.677 (95% CI 0.620–0.735). ROC curves demonstrated that the OS nomogram exhibits excellent predictive accuracy and discriminative ability. Calibration curves indicated strong consistency between the OS nomogram’s predicted survival rates and actual survival rates. Conclusions We established a survival prediction model for ATC, which can assist clinicians in assessing patient prognosis and making personalized treatment decisions.


  • Open Access

    Effect of chemotherapy on prognosis in patients with primary pancreatic signet ring cell carcinoma: A large real-world study based on machine learning

    by Kun Huang, Xinzhu Yuan, Pingwu Zhao, Yunshen He

    Background: Primary pancreatic signet ring cell carcinoma (PSRCC), an extremely rare histologic variant of pancreatic cancer, has a poor prognosis. This study aimed to investigate the prognostic value of chemotherapy in PSRCC. Methods: Patients with PSRCC between 2000 and 2019 were identified using the Surveillance Epidemiology and End Results (SEER) database. The main outcomes in this study were cancer-specific survival (CSS) and overall survival (OS). The baseline characteristics of patients were compared using Pearson’s Chi-square test. Kaplan-Meier analysis was used to generate the survival curves. Least absolute shrinkage and selection operator (LASSO), univariate and multivariate Cox regression models, and Random Survival Forest model were used to analyze the prognostic variables for OS and CSS. The variance inflation factors (VIFs) were used to analyze whether there was an overfitting problem. Results: A total of 588 patients were identified. Chemotherapy was an independent prognostic factor for OS and CSS, and significantly associated with OS (HR = 0.33, 95% CI = 0.27–0.40, P <0.001) and CSS (HR = 0.32, 95% CI = 0.26–0.39, P <0.001). Conclusions: Chemotherapy showed beneficial effects on OS and CSS in patients with PSRCC and should be recommended in clinical practice.


  • Open Access

    Effect of chemotherapy on prognosis in patients with primary pancreatic signet ring cell carcinoma

    by Kun Huang, Xinzhu Yuan, Ning Jiang, Pingwu Zhao, Cheng-You Du

    Objective Primary pancreatic signet ring cell carcinoma (PSRCC) is an extremely rare histologic variant of pancreatic cancer with a worse prognosis. The present study aimed to investigate the prognostic value of chemotherapy for patients with PSRCC.Methods Patients with PSRCC between 2000 and 2019 were identified Using the Surveillance Epidemiology and End Results (SEER) database. The main outcomes in our study were cancer-specific survival (CSS) and overall survival (OS). Patient baseline characteristics were compared using Pearson’s chi-square test. Kaplan-Meier analysis was used to generate the survival curves. Least absolute shrinkage and selection operator (lasso) as well as univariate and multivariate Cox regression models were used to analyze the prognostic variables on OS and CSS.Results A total of 588 patients with PSRCC were identified. Chemotherapy was an independent prognostic factor for OS and CSS, and significantly associated with OS (HR = 0.33, 95% CI = 0.27–0.40, P < 0.001) and CSS (HR = 0.32, 95% CI = 0.26–0.39, P < 0.001).Conclusions Patients with PSRCC can benefit from chemotherapy, so it should be recommended to patients with PSRCC, especially those not suitable for surgery.